Y. Amy Siu

Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidances from Regulatory Agencies: Focus on CYP3A4 mRNA In Vitro Response Thresholds, Variability, and Clinical Relevance

Jane R. Kenny, Diane Ramsden, David B. Buckley et al. · Drug Metabolism and Disposition · 2018 · 68 citations · Full text

Medicine, Pharmacology, Toxicology +15

Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control

Niresh Hariparsad, Diane Ramsden, Jairam Palamanda et al. · Drug Metabolism and Disposition · 2017 · 46 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +11

Pharmacokinetic/pharmacodynamic drug–drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs

Maiko Nomoto, Cynthia Zamora, Edgar Schuck et al. · British Journal of Clinical Pharmacology · 2018 · 26 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Celecoxib is a substrate of CYP2D6: Impact on celecoxib metabolism in individuals with CYP2C9*3 variants

Y. Amy Siu, Ming‐Hong Hao, Vaishali Dixit et al. · Drug Metabolism and Pharmacokinetics · 2018 · 26 citations

Medicine, Pharmacokinetics, Pharmacology +8

Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Guidelines on Model Fitting and Recommendations on Time Course for In Vitro Cytochrome P450 Induction Studies Including Impact on Drug Interaction Risk Assessment

Simon Wong, Diane Ramsden, Shannon Dallas et al. · Drug Metabolism and Disposition · 2020 · 26 citations · Full text

Pharmacy, Pharmacology, Toxicology +17